Autopsy report · NCT01819428

NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma

“Low recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 8 months before it stopped.
• 22 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National OncoVenture

Sponsor type

University, hospital or other

Conditions

Adenocarcinoma of Lung Stage IIIB; Adenocarcinoma of Lung Stage IV

Interventions

NOV120101 (Poziotinib)

Participants

22

Sites

6

Countries

South Korea

Trials that died the same way

• Impact of Methadone on Prolonged Mechanical Ventilation in Patients on Continuous Treatment With Opioids
  “very low recruitment” (95% match in meaning)
• Study of Psychomotor Development and Attachment in Children Aged 6 to 30 Months With Oral Disorder
  “Recruitment too low” (92% match in meaning)
• Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors
  “Poor recruitment” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.